MS
AVTX icon

Maven Securities’s Avalo Therapeutics AVTX Stock Holding History

Maven Securities’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-387
Closed -$163K – 865
2023
Q1 		$163K Buy
+387
New +$305K ﹤0.01% 890
2021
Q4 		– Sell
-17
Closed -$109K – 843
2021
Q3 		$109K Buy
+17
New +$138K ﹤0.01% 990

Other funds holding AVTX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Maven Securities's AVTX Position: Q2 2023 in Review

Maven Securities sold out of Avalo Therapeutics (AVTX) in Q2 2023, closing a stake of 387 shares — an estimated $163K sold.

Maven Securities first reported a position in AVTX in Q3 2021 and held it in 2 quarters. The position peaked at $163K in Q1 2023. 22 funds tracked by Wall St. Rank hold AVTX as of Q2 2023.

  • Maven Securities reported no remaining Avalo Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Maven Securities sold 387 Avalo Therapeutics shares in Q2 2023, an estimated $163K.
  • Maven Securities first reported a position in Avalo Therapeutics in Q3 2021 and held it in 2 quarters.
  • Maven Securities's Avalo Therapeutics position peaked at $163K in Q1 2023.
  • 22 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2023.

Based on Maven Securities's 13F filing for Q2 2023, filed 4 Aug 2023.